Form 4: Olema Pharmaceuticals Director Ian T. Clark Acquires 23,000 Stock Options

Director Ian T. Clark acquired 23,000 stock options in Olema Pharmaceuticals on June 14, 2024.

Summary

• On June 14, 2024, Ian T. Clark, a director of Olema Pharmaceuticals, Inc., acquired 23,000 stock options.
• The exercise price of these options is $12.36.
• The options vest in 12 equal monthly installments starting from June 14, 2024, contingent upon continuous service.
• Full vesting occurs at the next annual meeting if not fully vested by then, also subject to continuous service.
• The options expire on June 14, 2034.
• Following the transaction, Clark directly owns 23,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is contingent upon the reporting person's continuous service, aligning their interests with the company's long-term performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring such filings can provide insights into management's sentiment and expectations regarding the company's prospects.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates